Molecular Partners AG announced that further preclinical data supporting the company's Radio DARPin Therapy Platform will be shared at the American Association for Cancer Research Annual Meeting held April 14-19 in Orlando, Florida. Data within the presentation demonstrate that both the affinity and small size of DARPins can have an impact on tumor penetration. In addition to this, the data highlights that surface engineering of the DARPin backbone is a promising strategy to strongly reduce the kidney accumulation of DARPins, without affecting tumor uptake.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.36 CHF | +0.30% | -1.03% | -2.33% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.33% | 122M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.23% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- Molecular Partners AG to Present Additional Preclinical Data Supporting the Company's Radio Darpin Therapy Platform At AACR